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Summary
In agriculture, antibiotics are used for the treatment
and prevention of livestock disease. Antibiotics per-
turb the bacterial gut composition but the extent of
these changes and potential consequences for animal
and human health is still debated. Six calves were
housed in a controlled environment. Three animals
received an injection of the antibiotic ﬂorfenicol
(Nuﬂor), and three received no treatment. Faecal sam-
ples were collected at 0, 3 and 7 days, and bacterial
communities were proﬁled to assess the impact of a
therapy on the gut microbiota. Phylogenetic analysis
(16S-rDNA) established that at day 7, antibiotic-treated
microbiota showed a 10-fold increase in facultative
anaerobic Escherichia spp, a signature of imbalanced
microbiota, dysbiosis. The antibiotic resistome
showed a high background of antibiotic resistance
genes, which did not signiﬁcantly change in response
to ﬂorfenicol. However, the maintenance of
Escherichia coli plasmid-encoded quinolone, oqxB
and propagation of mcr-2, and colistin resistance
genes were observed and conﬁrmed by Sanger
sequencing. The microbiota of treated animals was
enriched with energy harvesting bacteria, common to
obese microbial communities. We propose that antibi-
otic treatment of healthy animals leads to unbalanced,
disease- and obese-related microbiota that promotes
growth of E. coli carrying resistance genes on mobile
elements, potentially increasing the risk of transmis-
sion of antibiotic resistant bacteria to humans.
Introduction
The intestinal microbiota is critical for homeostasis in
humans and animals and represents a natural reservoir of
antibiotic resistance genes (Salyers et al., 2004; Dethlef-
sen et al., 2007; Sommer et al., 2009; Allen et al., 2010).
Antibiotics (AB) are commonly used in livestock farming
to prevent and treat infections as well as in developing
countries to support growth, despite promoting the rapid
development of multidrug-resistant pathogens including
those resistant to ‘antibiotics of last resort’, such as col-
istin (Cabello, 2006; McEwen, 2006; Martınez, 2008; Has-
man et al., 2015; Liu et al., 2016; Paterson and Harris,
2016). Also, it has long been thought that such treatments
directly select for bacteria resistant to the prescribed
antibiotic, leading to emergence of resistance determi-
nates speciﬁc to the administrated antibiotic (e.g. Hayden
et al., 2005; Sanchez Garcia et al., 2010; Endimiani et al.,
2011). However, AB treatment appears to cause the more
general imbalance of the microbiota dysbiosis that can
have additional effects, including a disproportional
increase in abundance of speciﬁc bacteria which may
carry mobile elements that contain multidrug resistance
genes (Barlow, 2009; Shin et al., 2015) and/or being
associated with obesity.
An overlooked aspect of the widespread use of antibi-
otics is how they affect the composition of the gut micro-
biota with relation to the host wellbeing. There is an
ever-growing body of evidence to support the role of the
gut ﬂora in human and animal health and disease
(Holmes et al., 2011). A balanced intestinal microbiota,
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generally dominated by obligate anaerobes due to the
hypoxic nature of the gut, is vital in maintaining home-
ostasis, energy metabolism and supplying essential bio-
molecules that are not synthesized by the host
(Zoetendal et al., 2004; Krajmalnik-Brown et al., 2012).
AB treatment is known to perturb the intestinal micro-
biota, in part due to elevating the oxygen level in the
colon (Meynell, 1963). AB treatment in mice (Saito,
1961), humans (Vollaard et al., 1992) and pigs (Looft
et al., 2012) has been associated with an expansion of
facultative anaerobes, disrupting anaerobiosis and
enhancing aerobic respiration. A disproportional increase
in abundance of certain Proteobacteria, such as faculta-
tive anaerobes like Escherichia coli in the gut is linked to
inﬂammation and obesity, can promote aerobic pathogen
colonization and enhance permeability of the colon, com-
promising the ability of microbiota to maintain a bal-
anced, protective bacterial community (Zoetendal et al.,
2004; Arumugam et al., 2011; Holmes et al., 2011; Shin
et al., 2015). Also, commensal facultative anaerobes
may carry a wide range of genes responsible for genetic
transfer, including resistance determinants to antibiotics
that have not been administrated (Looft et al., 2012),
therefore increasing the prevalence of ‘off-target’ antibi-
otic resistance. Changes in the composition of the gut
microbiota have also been linked to weight gain in ani-
mals and humans (Cromwell, 2002; Angelakis et al.,
2012; Million et al., 2013), and the effect on health how-
ever has continued to be overlooked. The bacterial gut
microbiota composition of obese mammals differs from
their lean counterparts, and it has been shown to be crit-
ical to both fat storage and host energy balance (Ley
et al., 2006; Turnbaugh et al., 2006). Interestingly, an
increase in body mass may occur without changes in
food consumption, strongly suggesting that the micro-
biota in the gut is crucial to obesity and its composition
inﬂuences the amount of energy derived from the diet
(B€ackhed et al., 2004). Hence, the obesity-associated
gut microbiota appears to be more efﬁcient in energy
extracting than a balanced bacterial counterpart. Such
evidence demonstrates that effects of the liberal use of
antibiotics have been long underestimated.
One of the emerging challenges with respect to AB-re-
sistant commensal bacteria is that they may carry mobile
resistance elements that had previously been thought to
be associated only with chromosomal mutations, for
example resistance to colistin which has now been found
to occur on mobile genetic elements (Liu et al., 2016).
While originally found in animals, colistin resistance has
already been reported in humans, making zoonotic
transmission a major public health concern. A similar
pattern of resistance has emerged for ﬂuoroquinolones.
The previous use of colistin and/or ﬂuoroquinolones in
livestock to promote growth has led to the rise of the
corresponding plasmid-mediated resistance determinants
in E. coli (Witte, 1998; Hansen et al., 2004; Zhao et al.,
2010; Liu et al., 2016; Shen et al., 2016; Partridge,
2017). However, AB-driven dysbiosis may further con-
tribute to the expansion of commensal and pathogenic
bacteria carrying a wide range of plasmid-mediated mul-
tidrug resistances which are highly mobile and capable
of self-transmission between agricultural and clinical set-
tings. Therefore, growth of bacteria that may be carrying
resistance genes on mobile elements due to dysbiosis in
the human food chain following antibiotic treatments
poses signiﬁcant risk to animals and humans (Shin
et al., 2015; Litvak et al., 2017) has long been over-
looked.
Here, calves housed and reared under controlled con-
ditions were exposed to preventive antibiotic therapy ﬂor-
fenicol; trade name Nuﬂor to assess the effects on
resistome and the gut microbiota. This is the ﬁrst report
of a molecular analysis of calf gut microbiota in response
to a preventive antibiotic therapy that predisposes ani-
mals to dysbiosis and disease, promoting the growth of
bacteria that carry highly mobile clinically relevant resis-
tances that can be transmitted to humans.
Results
Antibiotic treatment leads to an imbalanced microbial
community in the animal gut
Deep sequencing of the 18 samples produced
5 578 146 sequence reads of the V3–V4 hypervariable
regions of the bacterial 16S rDNA; 2 888 547 from medi-
cated and 2 689 599 from non-medicated calves. In
each sample, up to 10 different bacterial phyla (Fig. 1A)
were identiﬁed, along with methanogenic Archaea
Fig. 1. Phylogenetic analysis of the composition of faecal animal gut microbiota. (A) Phylum-level composition of non-medicated, control (s77c,
s61c and s62c) and medicated, injected with ﬂorfenicol (s63m, s66m and s76m) faecal microbiota samples before treatment (T0) and after the
antibiotic treatment, day 3 (T3) and day 7 (T7). The saccharolytic bacteria, Firmicutes and Bacteroidetes are the most abundant phyla, followed
by Saccharibacteria, Tenericutes, Spirochaetes with minor contributors Actinobacteria, Proteobacteria, Verrucomicrobia and Cyanobacteria. (B)
Firmicutes and Bacteroidetes phyla composition in injected and control samples. (C) Bacterial composition of less abundant phylum in injected
and (D) control samples over time-course, To, T3 and T7. The y-axis is the percentage of rDNA-seq reads over the total number of reads.
rDNA-seq reads from three medicated and non-medicated faecal samples were quantiﬁed and presented with the standard error (SE) of the
mean (n = 3) at 95% conﬁdence intervals. The asterisk (*) indicates a statistically signiﬁcant difference for injected samples over the time-
course comparing with the control (non-medicated; the intervention interaction effect between the two groups, P = 0.006)
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(Fig. 2). The predominant phyla were Firmicutes
(64  1.7%) and Bacteroidetes (26  2.6%; Fig. 1A and
1), which have been shown to be the most abundant in
human and animal guts (Eckburg et al., 2005; Sun and
Chang, 2014). At lower prevalence were Saccharibacte-
ria, Tenericutes, Spirochaetes, Actinobacteria, Pro-
teobacteria, Verrucomicrobia and Cyanobacteria. Except
Proteobacteria, the overall prevalence of phyla did not
signiﬁcantly change in response to antibiotic treatment
(Fig. 1B and 1).
AB treatment changed the composition of gut micro-
biota through a 10-fold rise in Proteobacteria by day 7
(P = 0.017), and this was a signiﬁcant shift compared
with non-medicated samples at day 7 (P = 0.022;
Fig. 3A). Results from repeated measures ANOVA indi-
cated a signiﬁcant intervention interaction (P = 0.006).
Post hoc pairwise comparisons indicated that there were
no signiﬁcant differences in the abundance of Proteobac-
teria between T0, T3 and T7 for the control group. The
injected group did not show an increase of the phylum
from T0 to T3. There was no signiﬁcant difference in the
Proteobacteria abundance between the two groups at T0
and T3; however, there was a signiﬁcant difference
between the two groups at T7 (P = 0.022). Such a shift
was mainly due to an expansion of the genus Escheri-
chia T0/ v T7 (P = 0.011) in response to AB (Fig. 3B).
For the injected group, there was a non-signiﬁcant trend
in increased Escherichia from T0 to T3 (P = 0.591).
There was no signiﬁcant difference in the Escherichia
abundance between the two groups at T0 and T3; how-
ever, there was a signiﬁcant difference between the two
groups at T7 (P = 0.032). The increase in E. coli was
conﬁrmed by semi-quantitative PCR of the correspond-
ing metagenomic DNAs targeting uidA, the gene encod-
ing for b-glucuronidase, a marker for E. coli
Supplementary information (Fig. S1). A signiﬁcant
increase in the prevalence of E. coli in the gut is a dis-
tinct feature of an imbalanced microbial community (Shin
et al., 2015).
The treatment led to selection of both methanogenic
Archaea (T0 v T7 P = 0.003; Fig. 2) and Prevotellaceae
spp (T0 vT3 P = 0.029, T0 v T7 P = 0.045, T3 v T7
P = 0.022; Fig. 4). The control group did not show signif-
icant differences in the abundance of both Archaea and
Prevotellaceae spp over the time-course. However, there
were signiﬁcant differences between the two groups at
T7 (P = 0.025) and T3 (P = 0.03) for Archaea and
Prevotellaceae spp correspondently. Repeated
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Fig. 2. Abundance of methanogenic Archaea (Methanobacteriales spp) is signiﬁcantly increased by T7 in response to the ﬂorfenicol treatment
(*, To/T7 P = 0.003 and was signiﬁcantly higher comparing with non-medicated at day 7 (*,T7 injected v T7 non-medicated, P = 0.025). (A) Time-
course over seven days for injected (medicated) and control (non-medicated) samples was plotted. (B) Euryarchaeota (Archaea) composition,
percentage of sequences normalized to the total number of reads shown. Error bars present SE of the mean (n = 3) at 95% conﬁdence inter-
vals
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measures ANOVA indicated a signiﬁcant intervention
interaction (P = 0.013) for Prevotellaceae spp. The post
hoc pairwise comparisons indicated at T3 point the abun-
dance of Prevotellaceae spp in the injected group was
signiﬁcantly higher comparing with the non-medicated
one (P = 0.013), while there were no differences
between groups at T0 and T7. For Archaea, there was a
signiﬁcant increase from T0 to T7 for the injected group
(P = 0.003). This is a distinct feature of obesity-associ-
ated microbiota due to the ability of methanogenic
Archaea to enhance the production of short-chain fatty
acids (Samuel and Gordon, 2006; Karlsson et al., 2012).
This is consistent with the composition of the calves’ gut
microbiota treated with ﬂorfenicol demonstrating
increased in energy harvesting bacteria, resembling
microbiota of obese/overweigh animals and humans.
Emergence of E. coli carrying mobile mcr-2,
maintenance of oqxB genes and resistance to clinical
antibiotics in response to ﬂorfenicol
Whole metagenome sequencing of samples at day To
and T7 resulted in 27 231 751 trimmed sequences for
one non-medicated and 32 598 705 for two medicated
animals. Diverse antibiotic resistance genes were identi-
ﬁed in faecal samples of both non-medicated (Table S1)
and medicated animals (Tables S2 and S3) with, overall,
no signiﬁcant differences between them, with two excep-
tions. First, at day seven, the gut microbiota of the two
medicated animals contained detectable amounts of the
mcr-2 gene (Xavier et al., 2016) DNA-seq reads, phos-
phoethanolamine-lipid A transferase MCR-2 (NCBI Ref-
erence: NG_051171.1; Tables S2 and S3). The
emergence of mcr-2 alleles in response to ﬂorfenicol
coincides with a 10-fold increase in the abundance of
E. coli, and mcr-2 was originally found on the E. coli
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Fig. 3. Florfenicol treatment leads to dysbiosis, an expansion of
Proteobacteria. (A) Phylum-level composition in the gut (*, To v T7
P = 0.01) was changed signiﬁcantly in response to AB treatment
(P = 0.017) in contrast to the control group (P = 0.7). A 10-fold
increase upon the AB treatment at T7 was observed comparing with
the non-medicated T7 sample (T7 injected v T7 non-medicated,
P = 0.022) (B) Genus-level composition of Escherichia in response
to the AB treatment (*, To v T7, P ˂ 0.05 (0.011)) was signiﬁcantly
higher at T7 comparing with non-medicated samples (T7 injected v
T7 non-medicated, P = 0.032). No signiﬁcant differences for control
samples (P = 0.913) and between T0 v T3 for injected samples
(P = 0.591) were observed. Details are as in Fig. 1
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Fig. 4. Florfenicol treatment leads to selection of obese-related
microbiota. Florfenicol treatment leads to a signiﬁcant increase in
relative abundance of the family Prevotellaceae (phylum Bacteroide-
tes; P = 0.013, the intervention interaction effect). Details are as in
Fig. 1. Injected: *, To v T3 P = 0.029, T3 v T7 P = 0.022; T3 injected v
T3 non-medicated P = 0.03. No signiﬁcant differences (P > 0.033,
0.045) for control samples were observed
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plasmid pKP37-BE (NCBI Reference: LT598652.1. 38).
Nested PCR followed by Sanger sequencing of the ﬁrst
683 nucleotides of the gene conﬁrmed a 100% match to
the mcr-2 gene (Fig. S2), starting non-medicated sam-
ples at To displayed no PCR products. While we were
not able to conﬁrm the presence of the pKP37-BE plas-
mid in the samples by PCR, it is very likely that the mcr-
2 allele occurs on this vector due to the complete match
of the identiﬁed sequence to the reference.
Second, analysis of the prevalence of quinolone resis-
tance genes revealed that DNA-seq reads for oqxB, a
constituent of an RND-type multidrug efﬂux pump resis-
tance to olaquindox in E. coli (Hansen et al., 2004), were
equally present in all tested To samples. Surprisingly,
the oqxB gene was detected by neither DNA-seq nor
PCR in the non-medicated sample at day seven. How-
ever, upon the ﬂorfenicol treatment, the number of oqxB
sequences for the two medicated samples at To and T7
was being maintained at a similar level 36  9.5 and
43.7  0.4 respectively (Table S4). It has been reported
that the oqxB gene occurs on the plasmid pOLA52
(NCBI Reference: EU370913.1; Sørensen et al., 2003).
Sanger sequencing of the nested PCR fragments of
386 bp (48049 to 48434 nt positions within pOLA52), the
sequence which is predicted to be within the drug efﬂux
channel (Sun et al., 2014; Fig. S3), of the metagenomic
DNA of medicated samples, conﬁrms the presence of
the oqxB gene at T7. At the DNA level, silent and mis-
sense point mutations were found that translated into
four sets of mutated polypeptides (Fig. 5). The G148N
amino acid substitution was the main feature of all
sequenced clones which resulted in appearance of the
PN motif. The G148N substitution also occurred on its
own, along with L90I or T92A and alongside both L90I
and D152N. Hence, polypeptides with either single, dou-
ble or triple amino acid substitutions were present in the
metagenomic oqxB gene. Analysis using a combination
of molecular modelling and Monte Carlo reﬁnement was
used to examine the potential structural consequences
associated with substitutions at each locus. It was
revealed that the mutations can be divided into two clus-
ters G148N (Fig. S4), D152N (Fig. S5) and L90I/T91A
(Fig. S6) and are located in the drug efﬂux channel and
at the interface between OqxA and OqxB respectively.
L90I/T91A, despite the apparent physiochemical similar-
ity between Leu and Iso the b-branched nature of Iso,
can inﬂuence the secondary structure formation in b-
sheets and a-helices. In silico mutagenesis and Rosetta
reﬁnement were used to mimic the mutation (L90I)
observed in the cluster. Twenty-seven of the 30 indepen-
dent Monte Carlo simulations revealed a break in the b-
sheets and subsequent reorientation of a juxtaposed
helical region (P56-A70). This region of helix is directly
exposed to the drug efﬂux channel and has the potential
to alter its shape. Examination of the effect of T91A
which is also located in this region revealed in contrast,
the in silico mutation did not have a marked effect on
the secondary structure at this locus. However, the sub-
stitution with an Ala at this position does result in the
loss of interaction through a hydrogen bond with Ser82
in a juxtaposed b-sheets and reordering of this area.
This also results in the change of position in the helical
region P56-A70 and subsequent reordering resulting in a
larger aperture in the efﬂux channel. G148N/D152N, the
location of the second cluster of mutations, sits at the
interface between the membrane-bound OqxB and sol-
uble scaffold protein OqxA of the complex. G148N is
located at the interface of 2 b-sheets. The in silico sub-
stitution of Asn at this locus results in a further inter b-
sheet interaction with Asp323 located on a juxtaposed b-
sheet. This further hydrogen bond represents an
increased stability of approximately 61kcal/mol in this
region of secondary structure. For D152N, this mutation
is also at the interface between OqxA and OqxB. Visual
inspection of the reference sequence reveals that this
position (A152) in OqxB is juxtaposed to a charged clus-
ter in an associated chain including an acid residue
A281. The substitution of Asn may provide a better com-
plementarity between the subunits which is reﬂected in
the molecular modelling with the two positions becoming
closer in the mutant receptor after reﬁnement compared
to the reference sequence. The additional interactions in
the mutated protein sequence will not only result in local
increases in stability but taken together also increase the
stability of the complex as a whole. The enhanced ther-
modynamic stability of the complex would be predicted
to lead to an increased protein half-life and as such
increase efﬂux capacity of the host.
The presence of the pOLA52 plasmid in the treated
samples at T7 was conﬁrmed by Sanger sequencing of
nested PCRs of the metagenomic DNA targeting a ran-
domly selected sequence of 215 bp within the plasmid.
These results strongly suggest that preventive antibiotic
treatment of healthy animals promotes growth of E. coli
that carry clinically relevant resistance genes on mobile
elements, increasing a risk of the spread of resistance
within farm and human populations.
Discussion
We investigated the impact of a preventive antibiotic
(ﬂorfenicol) on the gut microbiome and antibiotic resis-
tome of healthy calves. The results show that such ther-
apy has a pleiotropic effect on the gut microbiota
composition leading to emergence of an obesogenic and
dysanaerobic, disease prone bacterial community that
carries clinically relevant mobile antibiotic resistance
determinates. First, the selection of obesity-related
ª 2019 The Authors. Microbial Biotechnology published by John Wiley & Sons Ltd and Society for Applied Microbiology.
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microbes without changes in the diet was observed, sug-
gesting that antibiotic treatments may be a key determin-
ing factor of obesity. Second, dysbiosis was found
during the treatment with an expansion of facultative
anaerobes that may trigger inﬂammation and affect the
immune system. Finally, the observed dysbiosis was
associated with a signiﬁcant expansion of E. coli carry-
ing clinically important mobile antibiotic resistance
genes. This is consistent with a real risk of the spreading
of E. coli carrying resistance determinants within and
between environmental and clinical settings that will
diminish the ability to treat bacterial infections with antibi-
otics. The data strongly argue that the primary outcome
of AB therapy is dysbiosis, which in turn propagates
obese state bacteria and thus may facilitate the spread
of a wide range of resistance genes due to enhancing
the aerobic environment of the gut.
The phyla Firmicutes and Bacteroidetes comprise
around 90% of the gut microbiota of the calves. These
provide the animals with energy harvested from indi-
gestible and poorly digestible polysaccharides (Eckburg
et al., 2005; Ley et al., 2008). Previous analyses of ani-
mal and human microbiota have shown that antibiotic
treatments can cause transient changes in the composi-
tion of the gut microbiota (Sommer and Dantas, 2011).
Antibiotics such as tetracyclines, glycopeptides and
macrolides administered individually or in combination
(e.g. ASP250) have often been used to promote weight
gain in animals (Moore et al., 1946; Cromwell, 2002;
Looft et al., 2012). Equally, weight gain in humans, both
adults and children (Santacruz et al., 2010; Angelakis
et al., 2012; Gao et al., 2015), has been observed with
some of antibiotics (e.g. tetracycline, macrolides, sulpho-
namides); however, these effects on health have been
disregarded until recently. It is not clear whether the
observed antibiotic-mediated weight gain is a result of
improved, infection-free gut microbiota, the perturbation
of its composition or a combination of both. There is
however mounting evidence to support the view that
changes in the composition of the gut microbiota play a
key role in the amount of energy produced from the diet
without any changes in nutrient consumption. Signiﬁcant
increases in the abundance of both methanogenic
Archaea and Prevotellaceae spp (which have been
observed following antibiotic treatment in this work) are
also linked to obesity in humans and animals. Prevotel-
laceae are H2-producing Bacteroidetes (Zhang et al.,
2009; Everard et al., 2013) which during the fermentation
process enable accumulation of H2, reducing the yield of
ATP and leading to a gradual decrease in fermentation
efﬁciency. The methanogenic Archaea are believed to
not only have a role in obesity through promoting caloric
intake from otherwise indigestible polysaccharides
(Samuel and Gordon, 2006; Turnbaugh et al., 2006;
Dridi et al., 2011), but alongside an increase in Prevotel-
laceae can utilize the excess H2 to produce acetate, a
highly absorbed short-chain fatty acid (Chakraborti,
2015). Hence, the coexistence of Prevotellaceae with
methanogenic Archaea species in the gut of obese
mammals allows for greater efﬁciency of dietary polysac-
charide fermentation and increases their conversion into
short-chain fatty acids, leading to excessive energy stor-
age. It has been suggested that Bacteria–Archaea syn-
trophy may be a novel biomarker of susceptibility to
obesity (Zhang et al., 2009). In this study, the improved
energy harvesting capacity of the calves’ gut microbiota
was found to occur without any diet alteration. This is
consistent with the idea that an increase in the body fat
may occur without any increase in food intake (B€ackhed
et al., 2004) and supports the view that the bacterial
composition of the gut drives the energy harvesting from
the diet.
In the healthy mammalian gut, the hypoxic environ-
ment governs the composition of the bacterial commu-
nity, favouring obligate anaerobes such as Firmicutes
and Bacteroidetes. In turn, they utilize oxygen via b-oxi-
dation of microbiota-produced butyrate to carbon dioxide,
the main energy production pathway which is critical for
the development of the host immune system. Hence, a
disruption of anaerobiosis (dysanaerobiosis) due to
inﬂammation (Seksik et al., 2003; Krogius-Kurikka et al.,
2009; Wang et al., 2012; Fei and Zhao, 2013) or treat-
ment of infections with antibiotics, (Bohnhoff et al., 1954;
Saito, 1961; Vollaard et al., 1992) for example, leads to
an increased oxygenation of the colon and expansion of
facultative anaerobic Proteobacteria via aerobic
67-LEEAINGVENMMYMKSVAGSDGVL
90I
VT
92A
TVTFRPGTDPDQAQVQVQNRVAQAEARLPEDVRR
LGITTQKQSPTLTLVVHLFSPG
148N
GKYD
152N
SLYMRNYATLKVKDELARLPGVGQIQIFGSGEYAMRVWL
DPN-194
Fig. 5. The protein sequence of the metagenomic OqxB gene found on the E. coli plasmid pOLA52 (EU370913.1:48049-48434 nucleotide posi-
tions). The cloned DNA Sanger sequences were translated into amino acid sequences by using the NCBI ExPASy Translation Tool. The 128
amino acid translated sequence of the N-terminus (from the 67th to 194th amino acid) is presented. The four different types of amino acid muta-
tions found in the metagenomic sequences are shown in red with superscript letter showing the amino acid substitutions, L90I, T92A, G148N
and D152N. The G148N mutation (underlined) was found in all sequenced clones
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respiration. During dysbiosis, energy is also obtained
through anaerobic glycolysis, (Donohoe et al., 2012)
which does not require oxygen leading to increased
epithelial oxygenation (Cabello, 2006). The resultant
dysanaerobiosis, an increase of oxygen that disrupts
anaerobic environment in the gut, would enable selection
for facultative anaerobes, including commensal and
pathogenic E. coli by aerobic respiration. In this study,
ﬂorfenicol treatment caused an abnormal escalation of
Proteobacteria (mainly E. coli), resulting in dysbiosis of
the gut microbial community which can have a number
of consequences as it enhances the risk of disease
(Shin et al., 2015; Litvak et al., 2017). Escherichia spp
continually produce ethanol which increases the perme-
ability of the intestinal wall and promotes colonization by
obligate aerobes, characteristics linked to inﬂammation
and obesity. This can lead to certain environmental tox-
ins such as dimethylarsine which can be metabolized by
E. coli to produce toxic micrometabolites, potential car-
cinogens of the gut (Yamanaka et al., 1989). Increased
oxygen availability which promotes an expansion of
E. coli can also pave the way for growth of aerobic
pathogens, hence offsetting the beneﬁt of using preven-
tive AB therapies. Furthermore, E. coli are also a poten-
tial human pathogen that can carry antibiotic resistance
determinants on mobile elements, raising a possibility of
spreading resistance within and between communities.
Taken together, an antibiotic-induced dysbiotic expan-
sion of facultative anaerobic E. coli can predispose the
host to disease, such as intestinal inﬂammation and can-
cer. It also can drive an Enterobacteriaceae enteric
pathogen colonization which carries clinically relevant
transmissible antibacterial resistances. Therefore, prac-
tices of a preventive antibiotic treatment of healthy ani-
mals must consider the potential threat to animal health
as well as a high risk of zoonotic transfer of pathogens
carrying mobile resistances to the human population.
Antibiotic therapy in livestock plays a key role in the
selection of resistant bacteria (Witte, 1998) that can be
transmitted between animals, humans and the environ-
ment (Cabello, 2006). Recently, the mcr-1 allele confer-
ring a novel plasmid-borne colistin resistance gene was
discovered in food animals (Liu et al., 2016) and it has
now been detected across all continents (Acrilla et al.,
2016; Hu et al., 2016; Olaitan et al., 2016; Webb et al.,
2016). The mcr-1 resistance gene is found on a highly
transmissible plasmid, namely IncX4 which is a narrow
host range mobile element of Enterobacteriaceae with a
lack of ﬁtness burden on bacterial host (Liu et al., 2016).
Recent evidence strongly suggests transfer of mcr-1
from animals to humans while it also can be spread in
hospitals without colistin pressure (Paterson and Harris,
2016; Al-Tawﬁq et al., 2017; references therein Sun
et al., 2018). Subsequently, mcr-2, another plasmid-
mediated colistin resistance gene, has been identiﬁed in
porcine and bovine colistin-resistant E. coli (Xavier et al.,
2016). Like mcr-1, mcr-2 is a phosphoethanolamine
transferase which also occurs on an IncX4 plasmid
(pKP37-BE) that makes this resistance highly transmissi-
ble. While we have not been able to conﬁrm the pres-
ence of pKP37-BE in the samples where PCR clones
containing the mcr-2 sequences were identiﬁed (proba-
bly due to still low abundance of the DNA), it is very
likely that mcr-2 found in this study is also occurring on
pKP37-BE or another IncX4 plasmid. This is the ﬁrst
case of the emergence of the mcr-2 allele in the UK and
in livestock in response to antibiotic treatment. Impor-
tantly, cows at the farm descended from stock pur-
chased from Belgium where the ﬁrst emergence of the
mcr-2 allele was discovered (Xavier et al., 2016). The
ﬁnding of this work that 10-month-old calves (the ﬁrst
generation which has not been subjected to antibiotic
pressure before) microbiota possess mcr-2, which is
likely to have originated in Belgium, this implies that the
resistance allele has come vertically from their mother
and that mcr-2 is as stable as mcr-1 due to the allele
being present without AB pressure (Hu et al., 2016).
However, mcr-2 transmission via an environmental route
within the farm cannot be ruled out. This strongly argues
that antibiotic resistance determinants can also be
spread due to international livestock trading. Therefore,
this ﬁnding strongly supports a view that screening for
stable antibiotic resistances in agriculture, such as mcr
alleles (Xavier et al., 2016), should be included in epi-
demiological surveillance to monitor and control the dis-
semination of animal-borne resistance which is of clinical
relevance in humans.
Efﬂux pumps are associated with resistance to multi-
ple antimicrobial agents due to their ability to efﬁciently
extrude a broad range of chemicals from the bacterial
cell, thereby lowering the intracellular level of antibiotics.
This mechanism of resistance is seen as the ﬁrst line of
defence which plays a key role in the selection of novel
resistance genes. This gives the cell a time to develop a
targeted (multi)drug resistance to higher concentrations
of the antibiotic and/or drives the accumulation of addi-
tional gain-of-resistance mechanisms. Moreover, efﬂux
pump genes can occur on mobile elements that can be
transmitted to pathogenic bacteria (Louw et al., 2009;
Martinez, 2009; Machado et al., 2012; Schmalstieg
et al., 2012; Gumbo, 2013). The cloned and sequenced
region of 312 nts, from 271 to 583 nts, of the metage-
nomic oqxB gene is a part of the predicted efﬂux pump
domain. Based on the crystal structure of the E. coli
AcrB protein, the E. coli chromosomal efﬂux system,
AcrAB-TolC (Murakami et al., 2002), we have developed
a model of the OqxA/B drug efﬂux transporter. The V89-
N194 sequenced region of the oqxB spans two regions
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of the protein which are critically involved with drug recog-
nition/removal and intra/inter-subunit stability. The posi-
tions Leu90 and Thr91 are located in the RGD region of
the protein which is responsible for substrate recognition
and ultimately antibiotic removal from the host. Mutations
in this region may alter the poly-substrate speciﬁcity of
the transporter but based on the increase diameter of the
efﬂux channel a higher rate of antibiotic removal may be
predicted. In addition to this, further mutations at positions
Gly148 and Asp152 in OqxB result in enhanced thermo-
dynamic and kinetic stability of the complex as a whole
through additional intra- and inter-molecular interactions.
Collectively, these mutations would give rise to an efﬂux
pump which is predicted to have both a longer half-life
and also an enhanced ability to remove drugs from the
host. The oqxAB operon carries a resistance-nodulation-
cell division-type efﬂux pump that confers resistance to
the growth promoter olaquindox as well as to ampicillin
and chloramphenicol (Sørensen et al., 2003). In this
study, the identiﬁed oqxB gene of the oqxAB-encoded
pump resistance determinant occurs on an IncX1 plasmid,
pOLA52 which is also highly mobile due to the presence
of an IS26 element and a T3 transposon (Sørensen
et al., 2008). Alarmingly, oqxAB-positive commensal
E. coli isolates have been found among farmworkers who
have undergone no previous antibiotic treatment or been
admitted to the hospital, suggesting horizontal transfer of
the oqxAB resistance (van den Bogaard et al., 2001;
Zhao et al., 2010). Direct transmission of oqxAB-positive
E. coli between humans and livestock has also been
reported (Moodley and Guardabassi, 2009). Thus, mainte-
nance of E. coli carrying oqxAB in animals in response to
ﬂorfenicol and possibly to other antibiotics may enhance
its spread to humans. This, in turn, may increase the risk
of horizontal transfer of resistance to human pathogens.
Implications
Florfenicol treatment of calves resulted in changes in the
gut microbiota, so that it resembles the one of obese
humans/animals without any diet alteration. Obesity is a
major public and clinical health concern affecting around
400 million people globally. While diet contributes to the
diversity of the gut microbiota (B€ackhed et al., 2005) and
affects body mass, however, it is shown that this
increase may occur without changes in food consump-
tion (Ley et al., 2006). Hence, the improved energy har-
vesting capacity of the healthy gut microbiota in
response to the antibiotic may contribute to enhanced
energy intake while maintaining the same food intake.
Therefore, its potential impact on obesity is to be taken
into consideration by health professionals during the
treatment of clinical infections.
As a result of dysbiosis, a signiﬁcant enrichment in the
prevalence of facultative anaerobes such as E. coli in
response to a preventive antibiotic treatment increases
the risk of aerobic pathogen colonization in the healthy
host gut and predisposition to a number of diseases.
Additionally, dysbiosis changes permeability of the colon
and decreases the defence mechanisms of the host
against bacteria-driven toxins. Therefore, a positive out-
come of antibiotic preventive therapies, namely protect-
ing the host against potential infection, may inadvertently
lead to a number of severe side-effects. Of clinical con-
cern, the observed expansion of E. coli coincides with
the emergence and preservation of E. coli mobile-medi-
ated resistance determinants, a colistin resistance allele
mcr-2 and a member of the multidrug efﬂux pump oqxAB
operon, the oqxB gene, respectively (Hansen et al.,
2004; Xavier et al., 2016). These genes confer resis-
tance to antibiotics of ﬁrst choice (e.g. quinolones) and
last resort (e.g. colistin) to treat multidrug-resistant hospi-
tal bacterial infections. The emergence of the novel mcr-
2 gene on Belgian commercial farms where the AB ther-
apy is strictly regulated (Xavier et al., 2016) showed pri-
mary evidence of E. coli carrying mobile elements with
stable resistances, such as the mcr allele (Shen et al.,
2016) to preserve genes which might confer the host
bacteria novel adaptive properties, for example ability for
stable colonization in strictly anaerobic environment and/
or survive in response to AB pressure. The presence of
mcr-2 in the gut of animals on a small rural farm where
non-colistin prophylactic antibiotic therapy is commonly
used is consistent with the previous ﬁndings and its
emergence coincides with expansion of E. coli carrying
this resistance suggesting that mcr alleles are important
for adaptive responses. E. coli carrying efﬂux pump
resistance determinants, such as oqxAB, can be less
susceptible to a broad range of antibiotics due to acquir-
ing new mutations, hence enhancing their surviving
properties. Furthermore, the recently discovered plas-
mid-born mcr-1 already is found on extended-spectrum
b-lactamase multidrug resistance plasmids (e.g. Li et al.,
2018), while plasmid-mediated multidrug efﬂux cassettes
are also linked to multidrug-resistant infections in the
hospital setting (Kim et al., 2009). While it is shown that
originally these resistance elements have been selected
due to a direct effect of polymyxin and olaquindox to pro-
mote animal growth their enrichment in the animal gut in
response to ﬂorfenicol, a non-cognate class of antibiotic
was alarming. Nevertheless, this represents a collateral
effect of antibiotic therapies that may lead to an increase
in resistance to non-administered drugs (Looft et al.,
2012) driving the development and spread of a wide
range of clinical resistance regardless of the speciﬁcity
of antibiotics; mobilized colistin resistance determinants
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have already been identiﬁed in clinical settings. Identiﬁ-
cation of the plasmid-mediated mcr-2 and oqxB resis-
tances marks a paradigm shift in our understanding of
the spread and development of resistance as until
recently they were sequestered to the chromosome
(hence, were less likely to be associated with multidrug-
resistant plasmid-mediated infections which in turn were
relatively easy to treat with drugs that target the chromo-
somal genes) and capable of vertical transmission only.
Hence, routine screening for mobile resistance genes in
livestock must be considered as a prerequisite for any
farm using antibiotics as a preventative therapy on food
animals in order to contain the spread of plasmid-borne
resistance determinants. Based on our results, we would
argue that the short-term beneﬁt of a given preventive
antibiotic therapy must be carefully assessed and
weighed against the collateral effects on promoting
antibiotic resistance and that novel screening policies for
clinically important bacteria occurring in agricultural envi-
ronments are urgently required.
Experimental procedures
Samples
In this study, the 3Rs principles have been applied in
order to reduce the number of animals used. Six seven-
month-old calves were divided into two groups of three.
One group (‘medicated’) received an injection of Nuﬂor
(containing ﬂorfenicol, a ﬂuorinated synthetic analogue of
thiamphenicol) which is commonly used to prevent respi-
ratory tract infections in cattle (e.g. Mannheimia
haemolytica, Histophilus somni and Pasteurella multo-
cida), 40 mg/kg body weight, while the other group
(‘non-medicated’) received no antibiotics. The antibiotic
was subcutaneously injected by the college veterinarian
as per manufactory recommendation (MSD Animal
Health).The calves were housed in decontaminated and
highly controlled setting at the Moreton Morrell College
Farm, Warwickshire College. The Warwickshire College
Board approved the use of college animals for this
study. Animals were treated under the supervision of the
registered farm veterinarian and in accordance with the
Moreton Morrell College Farm guidelines based on the
revised Animals (Scientiﬁc Procedures) Act 1986 in the
UK and Directive 2010/63/EU in Europe. All animals
were fed the same diet (ad libitum hay and silage and
1 kg of concentrates/animal/day) throughout the study
and were not exposed to any antibiotic treatment prior to
the study. A week before the study, the medicated and
non-medicated calves were segregated into two sepa-
rate rooms to prevent cross-contamination. The cows
were observed by the college veterinarian during the
period of the study, and no changes in animal health
have been found after 7 days of the study. Detail of
sample handling is described in Appendix S1.
Genomic DNA isolation and sequencing
Total genomic DNA (gDNA) was extracted using the
QIAamp DNA Stool kit (QIAGEN). 0.2 g of cell pellet
was re-suspended in 180 ll of 1 9 PBS and processed
according to the manufacturer’s instructions. The con-
centration of puriﬁed gDNA was measured by spec-
trophotometry at A260. Total DNA was used for whole
(meta)genome shotgun sequencing and as template for
the ampliﬁcation and sequencing of the V3-V4 hypervari-
able regions of the bacterial 16S small subunit ribosomal
RNA gene for metagenomic proﬁling. Details of the
sequencing protocols, including primer sequences, are
provided in Appendix S1. All sequence data were sub-
mitted to the European Nucleotide Archive (ENA), under
the study accessions PRJEB33144 (for the 16S rRNA
data) and PRJEB33145 (for the whole metagenome
shotgun sequence data).
Metagenomic proﬁling of bacterial communities
For each sample, 2 9 300 bp sequencing read pairs
from 16S amplicons were aligned to each other using
ﬂash v1.2.11 (Magoc and Salzberg, 2011). Resulting
sequences were processed to identify and remove
ampliﬁcation primer sequences from their 50 and 30 ends,
retaining only those with an identiﬁed ampliﬁcation pri-
mer sequence at each end, using cutadapt v1.9.1 (Mar-
tin, 2011). Processed sequences containing undeﬁned
nucleotides (N’s) and those of unexpected size (<350 bp
or >450 bp) were removed. To balance sample sizes for
each time-course, read sets were randomly down-sam-
pled to match the size of the smallest of the three
libraries prior to clustering. In each size-matched read
set, sequences were de-replicated by clustering identical
sequences and clusters of size 1 (likely to be enriched
for erroneous sequences) were removed. The remaining
ﬁltered, de-replicated reads were clustered at 97 %
sequence identity. De-replication and clustering were
performed using vsearch v1.1.1 (Rognes et al., 2016).
Clusters were further ﬁltered to remove putative chimeric
sequences using the ‘uchime denovo’ option in vsearch.
The remaining, putatively non-chimeric, clusters were
given a taxonomic assignment using SINA (Pruesse
et al., 2012) using default parameters, the ‘search and
classify’ option and the SILVA database as the primary
source of taxon labels. In each case, results from SINA
were processed by trimming taxonomic labels to the
required rank and summing the read numbers for clus-
ters with identical labels.
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Proﬁling the bacterial community ‘resistome’ using
whole-genome metagenomic shotgun sequencing
To assay the ‘resistome’ in each sample, sets of resis-
tance-associated genes were obtained from Resﬁnder
(https://cge.cbs.dtu.dk/services/ResFinder/) and used to
make a set of databases suitable for use with BLAT
(Kent, 2002). Reads were processed by removing
sequencing library adapter sequences using cutadapt
v1.9.1 (Martin, 2011), retaining only reads longer than
50 bp and containing no ‘N’s after trimming. Trimmed
reads were converted to FASTA format and ‘de-repli-
cated’ (identical reads collapsed into one read), using
vsearch v1.1.1 (Pruesse et al., 2012). This was done to
(i) make later analysis more computationally efﬁcient and
(ii) enable artefacts such as PCR duplicates to be
accounted for in later analyses. De-replicated reads from
each sample were searched against each gene set
using BLAT (Kent, 2002). All reads and target genes
were translated in all six reading frames and aligned as
proteins in order to capture reads from species more dis-
tantly related from the ‘reference’ sequences. Reads
matching ‘reference’ sequences in each ‘database’ were
quantiﬁed as the number of unique sequence matches
(i.e. de-replicated reads) and the total number of
matches (i.e. including multiple identical reads) and
expressed as counts and as proportions of the total
library size.
Semi-quantitative PCR ampliﬁcation of 16S rRNA and
uidA genes
A signiﬁcant increase in the DNA-seq reads for Escheri-
chia spp. at T7 was validated by semi-quantitative PCR
for the uidA gene and using the 16S rRNA gene as a
normalization control. PCR conditions are presented in
Appendix S1.
PCR, cloning and Sanger sequencing of the mcr-2 and
oqxB genes
To conﬁrm the DNA-seq data with regard to the emer-
gence of the mcr-2 gene and presence or absence of
oqxB visualization of nested PCR bands followed by
cloning and Sanger sequencing was carried out. Details
of cloning approaches are described in Appendix S1.
Molecular modelling
Molecular models of OqxA and OqxB were generated
using the crystal structure of AcrAB-TolC Multidrug Efﬂux
Pump (PDB 5V5S.pdb) using Modeller (Sali and Blun-
dell, 1993). Hundred models were generated and initially
ranked using OPUS_PSP (Lu et al., 2008). Five top
scoring models were reﬁned using the membrane protein
module from Rosetta (Alford et al., 2015). Point muta-
tions were made to the wild-type sequence using
Rosetta. Changes in secondary structure and relative
motions of secondary structure elements were analysed
using an in-house python script.
Statistical analysis
rDNA-seq reads were normalized between samples to
total number of read of the samples and presented as
percentage of total reads. In order to examine any differ-
ences in bacterial compositions over time and between
treatment and control groups, a series of 2 (injected vs
control, non-medicated) 9 3 (time points) way repeated
measures ANOVAs (SPSS v.24) were conducted, and
Benjamini–Hochberg test, the false discovery rate (the
critical value of <0.033) method, was used (Glickman
et al., 2014). Where any signiﬁcant differences were evi-
dent, post hoc pairwise comparisons were employed to
determine where the differences lay and where appropri-
ate standard error at 95% conﬁdence interval was used.
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Fig. S1. Assessment of an increase in the E. coli level in
response to Nuﬂor treatment. A series of dilutions of the
same sets of gDNAs (240 ng, 120 ng or 60 ng) at To and
T7 for the 16S RNA- and uidA genes were used for the
semi-quantitative PCR ampliﬁcation. 1 and 3, a 573 nts
PCR fragment of uidA at T7 and To, correspondently; 2 and
4, a 500 nts PCR fragment of the 16S RNA gene at T7 and
To, respectively. From this analysis it was apparent that the
To uidA sample produced a signal <2% of the Nuﬂor treated
sample at day 7.
Fig. S2. Sanger sequencing of the nested PCR fragments
for ﬁrst 683 nucleotides of the mcr-2 gene conﬁrmed the
DNA-seq data for the emergence of the mcr-2 allele.
Fig. S3. A molecular model of the OqxA/B efﬂux pump as
shown parallel to the membrane.
Fig. S4. The G148N mutation in OqxB.
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channel.
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